Suggested remit: To appraise the clinical and cost effectiveness of ibrutinib within its proposed marketing authorisation for untreated mantle cell lymphoma.
Please note that following on from information provided to NICE by the company in April 2023 , the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1221
Project Team
- Project lead
- Michelle Adhémar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 November 2024 | Discontinued. Please note that following on from information provided to NICE by the company in April 2023 , the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 04 April 2023 | Note added to the project documents |
| 25 August 2022 | Suspended. The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of ibrutinib for untreated mantle cell lymphoma ID1221. The company that market ibrutinib have informed NICE that it will not provide an evidence submission for the evaluation. In light of this information NICE will not be progressing with the scoping exercise. Please accept our apologies for any inconvenience this may cause. |
| 02 August 2022 | Note added to the project documents |
| 30 May 2018 | Note added to the project documents |
| 26 June 2017 | In progress. Topic referred |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual